Newsroom

#Epilepsy is the most common serious neurological condition, affecting more than half a million people in the UK. That is why UCB is collaborating with @epilepsysociety to address this problem. https://t.co/p1Rr0oqLEO #ProudPartners #HarnessingGenetics #EpilepsyFutures https://t.co/o3wLSw1Io8

Find out more about our new genomic partnership with the UK @epilepsysociety – which follows UCB’s commitment to invest £1 billion into the UK life-sciences sector over the next five years. https://t.co/p1Rr0oqLEO #StrongerTogether #HarnessingGenetics #EpilepsyFutures https://t.co/jYBGsYnOoT

Deletions or duplications in a person’s genome are important risk factors for epilepsy. By identifying these gene alterations, we could change the way #epilepsy is treated. Curious to learn more? Click here: https://t.co/p1Rr0oqLEO #StrongerTogether #HarnessingGenetics https://t.co/7OzuYWK5lR

#DYK? By analysing genetic causes of epilepsy, it is possible to develop personalised treatment relevant to patients’ genetic characteristics. This is what we’re doing as part of a new genomics research partnership. Find out more here https://t.co/p1Rr0oqLEO #EpilepsyFutures https://t.co/NxJYHrKrtH